Discover Portal

Discover the latest research

Results 1 - 1 of 1 (0.0 secs)
NIHR Signal Chemotherapy for people with recurrent stomach and oesophageal cancers can prolong survival by two to three months
This meta-analysis provides high quality evidence that second-line chemotherapy with supportive care can boost survival by about two months. In the three trials included, two types of chemotherapy were investigated for people with recurrent gastric cancers and compared to supportive care alone. Not all patients benefited from chemotherapy – over a third did not live longer or suffered side effects. A number of predictive factors were assessed that could be used for deciding which patients...
1-1 / 1
search results
1 - 1 in 0.000 seconds
Publication Type
Journal Source
  •  1 
  •  1 
  •  1 
  •  1 
View RSS Feed

Create an RSS feed based on your search.
This will update as new items are added.

Click here